Pharmacyte Biotech Inc (OTCMKTS:PMCB) may not be as large as many other biotech firms around the world, but the innovative technologies used by it are attracting some of the greatest minds of the industry. As per the reports, the company has been evolving ever since it came into existence, something that most of its rivals lag behind.
Among many oncologists to join the firm, the latest is Dr. Manuel Hidalgo. He is one of the well-known laboratory and clinical investigators in abdominal cancers. As of now, he is one of the top three pancreatic cancer specialists in the world. Not long ago, Hidalgo was named as one of the members of Pharmacyte’s Scientific Advisory Board.
Who Else Has joined The Company
Other experts who are attached to Pharmacyte Biotech in one way or another include names like Dr. Daniel Von Hoff of TD2 in Scottsdale, Arizona and Dr. Matthias Löhr of the Karolinska Institute in Sweden. All three of these experts want to help Pharmacyte Biotech in finding world class solutions to treat cancer and save as many lives as possible.
Meanwhile another renowned firm Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has decided to execute a reverse stock split as part of its preparation for uplisting to NASDAQ Marketplace. As per the reports, the company looks forward to proceeding with a consolidation of outstanding shares based on one post-consolidation outstanding share for every ten pre-consolidated shares. The procedure will commence upon fulfillment of all the regulatory requirements. NASDAQ can accept or reject company’s application without any notice.
Continuous hard work and persistence reward amazingly. The latest evidence of it is the announcement made by USANA Health Sciences, Inc. (NYSE:USNA) regarding its nomination in Utah Business Fast 50 List. The list makes room for top fifty companies in the Utah area based on how fast they grow on YOY basis. It’s the 8th consecutive occasion when USANA has made it to the list of fastest growing companies in the state.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: